AKT1 and head and neck squamous cell carcinoma: Targeting multiple dysregulated oncogenic pathways simultaneously through combination therapies utilizing an Hsp90/hetero chaperone complex inhibitor like WGA-TA, may also be effective in overcoming cisplatin resistance and provide a more durable treatment response, as we have demonstrated that WGA-TA targets key resistance pathways in HNSCC, namely MAPK and PI3K/Akt/mTOR.